Quick Answer
Avalo Therapeutics, Inc. reported Long Term Debt of $14.33 million for the year ending 2018.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2019.
- XBRL data for this metric is available from 2014 to 2018 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $3.20 million | Q1 2016: $1.49 million | Q2 2016: $611.1 thousand | Q1 2018: $14.59 million | Q2 2018: $14.38 million | Q3 2018: $14.35 million | Q4 2018: $14.33 million | Q1 2019: $14.30 million | Q2 2019: $14.28 million | Q3 2019: $14.25 million.
- Over the full 5 years of available data (2014 to 2018), Avalo Therapeutics, Inc.'s Long Term Debt has grown by 169.9%.
- Historical annual values: Fiscal year 2018: $14.33 million | Fiscal year 2017: $0.00 | Fiscal year 2016: $0.00 | Fiscal year 2015: $2.35 million | Fiscal year 2014: $5.31 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: